-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyowa Kirin says Phase 2 nAMD study of KHK4951 eye drops misses primary endpoint

PUBT·09/08/2026 07:16:36
Listen to the news
Kyowa Kirin says Phase 2 nAMD study of KHK4951 eye drops misses primary endpoint
  • Kyowa Kirin released topline Phase 2 results for KHK4951 eye drops in neovascular age-related macular degeneration.
  • The study missed its primary goal, failing to show a clearer benefit for the higher-dose regimen versus the lower dose.
  • Even so, most treated patients maintained vision over about a year, supporting a potential maintenance approach following anti-VEGF injections.
  • Safety looked manageable, with no new safety concerns flagged, supporting continued evaluation in future studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.